Polycationic calixarene PTX013, a potent cytotoxic agent against tumors and drug resistant cancer
- 507 Downloads
Previously, we reported on the anti-tumor activities of two designed calixarene-based topomimetics (PTX008 and PTX009) of the amphipathic, angiostatic peptide Anginex. Here, we chemically modified the hydrophobic and hydrophilic faces of PTX008 and PTX009, and discovered new calixarene compounds that are more potent, cytotoxic anti-tumor agents. One of them, PTX013, is particularly effective at inhibiting the growth of several human cancer cell lines, as well as drug resistant cancer cells. Mechanistically, PTX013 induces cell cycle arrest in sub-G1 and G0/G1 phases of e.g. SQ20B cells, a radio-resistant human head and neck carcinoma model. In the syngeneic B16F10 melanoma tumor mouse model, PTX013 (0.5 mg/Kg) inhibits tumor growth by about 50-fold better than parent PTX008. A preliminary pharmacodynamics study strongly suggests that PTX013 exhibits good in vivo exposure and a relatively long half-life. Overall, this research contributes to the discovery of novel therapeutics as potentially useful agents against cancer in the clinic.
KeywordsCalixarenes Galectin-1 Structure-activity relationships Therapeutics
Human umbilical vein EC
Structural activity relationships
Phosphate buffered saline
This work was supported by research grants from the National institute of Health - National Cancer Institute (CA-096090 and CA-76497) and OncoEthix Inc. to KHM. ER and LA-X were supported by OncoEthix Inc., the Foundation Nelia & Amadeo Barleta (FNAB), and the Association pour la Recherche & l’Enseignement en Cancérologie (AAREC).
Conflict of interest
Co-authors K.H. Mayo and J. R. MacDonald have a financial interest in PepTx, a pharmaceutical company that holds license to commercialize the PTX compounds
- 6.Dings RP, Van Laar ES, Loren M, Webber J, Zhang Y, Waters SJ, Macdonald JR, Mayo KH (2010) Inhibiting tumor growth by targeting tumor vasculature with galectin-1 antagonist anginex conjugated to the cytotoxic acylfulvene, 6-hydroxylpropylacylfulvene. Bioconjug Chem 21(1):20–27PubMedCrossRefGoogle Scholar
- 10.Bagnacani V, Franceschi V, Fantuzzi L, Casnati A, Donofrio G, Sansone F, Ungaro R (2012) Lower Rim Guanidinocalixarenes: Macrocyclic Nonviral Vectors for Cell Transfection. Bioconjug Chem 23:993-1002Google Scholar
- 16.Ghoul A, Serova M, Astorgues-Xerri L, Bieche I, Bousquet G, Varna M, Vidaud M, Phillips E, Weill S, Benhadji KA, Lokiec F, Cvitkovic E, Faivre S, Raymond E (2009) Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells. Cancer Res 69(10):4260–4269PubMedCrossRefGoogle Scholar
- 21.Serova M, Astorgues-Xerri L, Bieche I, Albert S, Vidaud M, Benhadji KA, Emami S, Vidaud D, Hammel P, Theou-Anton N, Gespach C, Faivre S, Raymond E (2010) Epithelial-to-mesenchymal transition and oncogenic Ras expression in resistance to the protein kinase Cbeta inhibitor enzastaurin in colon cancer cells. Mol Cancer Ther 9(5):1308–1317PubMedCrossRefGoogle Scholar